Colorectal Cancer Clinical Trials in Nashville

Showing 161-180 of 276 trials

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung Cancer+1 more

Eli Lilly and Company210 participantsStarted Sep 2016

Washington D.C., District of Columbia, United States • Sarasota, Florida, United States • Boston, Massachusetts, United States +10 more locations

COMPLETEDPhase 1< 1 mile

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664

The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Novartis Pharmaceuticals283 participantsStarted Aug 2016

Baltimore, Maryland, United States • Boston, Massachusetts, United States • Nashville, Tennessee, United States +20 more locations

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer Trials in Other Cities

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Other Conditions in Nashville